82258-36-4

Basic information

• Product Name: Etomoxir
• Synonyms: 2-[6-(4-Chlorophenoxy)hexyl]-2-oxiranecarboxylic acid ethyl ester;2-[6-(4-Chlorophenoxy)hexyl]oxirane-2-carboxylic acid ethyl ester;rac- Etomoxir
• CAS NO: 82258-36-4
• Molecular Formula: C₁₇H₂₃ClO₄
• Molecular Weight: 326.8151
• Product Categories: Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 82258-36-4.mol

Chemical Properties

• Boiling Point: 405°Cat760mmHg
• Flash Point: 142.6°C
• Appearance: /
• Density: 1.163g/cm³
• Vapor Pressure: 9.04E-07mmHg at 25°C
• Refractive Index: 1.519
• Storage Temp.: -20°C Freezer, Under Inert Atmosphere
• CAS DataBase Reference: Etomoxir(CAS DataBase Reference)
• NIST Chemistry Reference: Etomoxir(82258-36-4)
• EPA Substance Registry System: Etomoxir(82258-36-4)

Safety Data

• Hazardous Substances Data: 82258-36-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Etomoxir is used as an anti-diabetic drug for its ability to inhibit mitochondrial CPT1, which plays a crucial role in the regulation of fatty acid oxidation and glucose metabolism. This inhibition can help improve insulin sensitivity and reduce blood sugar levels in diabetic patients.
Used in Research Applications:
Etomoxir is used as a research tool to study the role of CPT1 in various biological processes, including fatty acid metabolism, energy production, and the development of metabolic disorders. By inhibiting CPT1, researchers can gain insights into the mechanisms underlying these processes and identify potential therapeutic targets for the treatment of related diseases.

InChI:InChI=1/C17H23ClO4/c1-2-20-16(19)17(13-22-17)11-5-3-4-6-12-21-15-9-7-14(18)8-10-15/h7-10H,2-6,11-13H2,1H3

Upstream product

• 82258-37-5 ethyl 2-[6-(p-chlorophenoxy)hexyl]acrylate 
• 57221-90-6 diethyl 2-<6-(tetrahydro-2H-pyranyloxy)hexyl>malonate 
• 213749-67-8 2-[6-(tetrahydro-pyran-2-yloxy)-hexyl]-malonic acid monoethyl ester 
• 213749-68-9 ethyl 2-<6-(tetrahydro-2H-pyranyloxy)hexyl>acrylate 
• 53963-10-3 2-[(6-bromohexyl)oxy]tetrahydro-2H-pyran 
• 213749-69-0 2-[6-(tetrahydro-pyran-2-yloxy)-hexyl]-oxirane-2-carboxylic acid ethyl ester 

Relevant articles and documents

The Baylis-Hillman chemistry in aqueous media: A convenient synthesis of 2-methylenealkanoates and alkanenitriles

A convenient, general and efficient synthesis of 2-methylenealkanoates and alkanenitriles is accomplished via the regioselective nucleophilic (SN2′) addition of hydride ion from NaBH4 to (2Z)-2-(bromomethyl)alk-2-enoates and 2-(bromomethyl)alk-2-enenitriles respectively in the presence of DABCO in environment friendly aqueous media. Synthesis of two hypoglycemic agents is also described.

Medicaments for the treatment of cardiac insufficiency

The use of oxirane carboxylic acids having the formula I: STR1 in which R1 and R2 are independently selected from hydrogen, halogen, straight-chain or branched 1-4C alkyl groups, straight-chain or branched 1-4C alkoxy groups, nitro or trifluoromethyl; R3 is hydrogen or straight-chain or branched 1-4C alkyl; Y is --O--(CH2)m --, where m is zero or a whole number from 1 to 4, and n is a whole number from 2 to 8, or a pharmaceutically acceptable salt thereof, is disclosed for treating heart insufficiency.

Versatile synthesis of 2-aryloxyalkyl-oxirane-2-carboxylate: Syntheses of ethyl 2-[6-(3-alkoxyphenoxy)-hexyl]oxirane-2-carboxylates

A versatile synthetic route to 2-aryloxyalkyl-oxirane-2-carboxylates as potential hypoglycemic agent has been developed via combination of dioxirane epoxidation of inactive olefin and facile aryl alkyl ether formation of the labile epoxy alcohol by Mitsun

Phospholipase A2 inhibitors

There is disclosed a method for the treatment of immunoinflammatory conditions, such as allergy, anaphylaxis, asthma and inflammation in mammals which comprises administering to a mammal so afflicated an effective amount of a compound having the formula:

Phospholipase A2 inhibitors

There is disclosed a method for the treatment of immunoinflammatory conditions, such as allergy, anaphylaxis, asthma and inflammation in mammals which comprises administering to a mammal so afflicted an effective amount of a compound having the formula: S

Phenalkoxyalkyl- and phenoxyalkyl-substituted oxiranecarboxylic acids, their use and medicaments containing them

Phenalkoxyalky- and phenoxyalkyl-substituted oxiranecarboxylic acids of the formula STR1 wherein R1 denotes a hydrogen atom (--H), a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group or a trifluoromethyl group, R2 has one of the meanings of R1, R3 denotes a hydrogen atom (--H) or a lower alkyl group, Y denotes --O--(CH2)m --, m denotes O or an integer from 1 to 4, and n denotes an integer from 2 to 8, with the proviso that the sum of m and n is an integer from 2 to 8, and the salts of the acids are new compounds. They display a hypoglycaemic action in warm-blooded animals. Processes for the preparation of the new compounds and of the intermediate products required for their preparation are described.